{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.6","upperLimit":"18.9","value":"18.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"Will employ Kaplan-Meier and Cox proportional hazard model methodology.","dispersionType":"Full Range","groups":[{"description":"Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nNivolumab: Given IV","id":"OG000","title":"Treatment (Nivolumab)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 1 year and 7 months","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}